CVS Cuts Price on EpiPen Alternative

When drug manufacturer, Mylan, raised the price of a pair of EpiPen’s to more than $600 last summer, patients in need scrambled for alternatives. The sharply higher price shocked parents last summer when they went to buy EpiPen devices for their children for the new school year.

Adrenaclick® offers a true alternative to the high-priced EpiPen. It has been declared safe by the FDA, national pharmacies sell it, and its list price is a third less than the EpiPen’s. Both the EpiPen auto-injectors and the authorized generic of Adrenaclick are approved by the Food and Drug Administration and contain the same active ingredient as other epinephrine auto-injector devices. Additionally, the American Academy of Allergy, Asthma, and Immunology includes generic Adrenaclick among therapeutic options in an anaphylaxis emergency action plan^*.

Impax Laboratories, the current owner of the rights to Adrenaclick, is spending millions of dollars to upgrade its assembly line to meet heightened demand for the product after the EpiPen price increases.

Now, CVS is offering the low-cost EpiPen Alternative, Adrenaclick, at all CVS Pharmacy locations

Patients can now purchase the authorized generic for Adrenaclick at a cash price of $109.99 for a two-pack – the lowest cash price in the market.

What should you do if you’re considering this switch? First, talk to your doctor about whether the authorized generic for Adrenaclick is a good fit for you specific medical condition. Your doctor can then write a prescription for an “epinephrine auto-injector” to ensure the lowest-cost product is filled. Patients who already have a prescription on file with CVS Pharmacy can ask their pharmacist to check with the doctor about making the change.

Click here to find Adrenaclick at the nearest CVS, or see pricing at other pharmacies.

* American Academy of Allergy, Asthma & Immunology

For the best Rx price on medications,
www.WellRx.com.

Compare prescription drug prices at more than
62,000 pharmacies nationwide.